Methods of treating inflammatory and autoimmune diseases with natalizumab | Patent Number 09493567

US 09493567 B2
Application Number12757305
Publication NumberUS 20100196318 A1
Pendency6 years, 7 months, 12 days
Filled DateApr 9, 2010
Priority DateFeb 28, 2006
Publication DateAug 5, 2010
Expiration DateFeb 27, 2026
Inventor/ApplicantsIvan Lieberburg
ExaminesGAMBEL, PHILLIP
Art Unit1644
Technology Center1600
Assignments
Biogen Ma Inc.
Current
Elan Pharmaceuticals Inc.
Original
Biogen
Original
Law Firm
You must be logged in to view
Login
Attorneys
Subscription-Only
View Concierge Program
Patent Prosecution report image

Empower your practice with Patexia Publication Prosecution IP Module.

Get access to our exclusive rankings and unlock powerful data.
Check our Latest ReportPurchase IP Module

Looking for a Publication Attorney?

Get in touch with our team or create your account to start exploring a network of over 120K attorneys.